此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项比较不同剂量的 NN0519-0130 药物降低 2 型糖尿病患者血糖效果的研究

2026年9月18日 更新者:Novo Nordisk A/S

每周一次 NNC0519-0130 对 2 型糖尿病参与者的安全性和有效性调查 - 剂量探索研究

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

研究概览

研究类型

介入性

注册 (实际的)

299

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Québec、加拿大、G1V 4T3
        • Diex Recherche Quebec
    • British Columbia
      • Kelowna、British Columbia、加拿大、V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Richmond、British Columbia、加拿大、V6V 2L1
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Victoria、British Columbia、加拿大、V8V 4A1
        • Cook Street Medical Clinic
    • New Brunswick
      • Moncton、New Brunswick、加拿大、E1G 1A7
        • G.A. Research Associates Ltd.
    • Nova Scotia
      • Halifax、Nova Scotia、加拿大、B3H 1V7
        • Nova Scotia Hlth Halifax
    • Ontario
      • Barrie、Ontario、加拿大、L4N 7L3
        • Centricity Research Barrie
      • Hamilton、Ontario、加拿大、L8L 5G8
        • Wharton Medical Clinic Clinical Trials (Hamilton)
      • Sarnia、Ontario、加拿大、N7T 4X3
        • London Road Diagnostic Clinic and Medical Centre
      • Toronto、Ontario、加拿大、M4G 3E8
        • Centricity Research Toronto
      • Toronto、Ontario、加拿大、M9V 4B4
        • Albion Finch Medical Centre
    • Quebec
      • Lévis、Quebec、加拿大、G6W 0M5
        • Centricity Research Quebec City
      • Mirabel、Quebec、加拿大、J7J 2K8
        • Centricity Research Mirabel
      • Montreal、Quebec、加拿大、H1Y 3H5
        • Recherche GCP Research
      • Saint-Laurent、Quebec、加拿大、H4T 1Z9
        • Centricity Research Ville St. Laurent VSL
    • Free State
      • Bloemfontein、Free State、南非、9301
        • Josha Research
    • Gauteng
      • Johannesburg、Gauteng、南非、2013
        • Wits Bara Clinical Trial Site
      • Midrand、Gauteng、南非、1685
        • Dr A Jacovides and Partners Inc
    • KwaZulu-Natal
      • Durban、KwaZulu-Natal、南非、4450
        • Dr Pillay's Rooms
      • eMkhomazi、KwaZulu-Natal、南非、4170
        • Dr T Padayachee
      • Bengaluru、印度、560054
        • MS Ramaiah
      • New Delhi、印度、110001
        • Lady Hardinge Medical College
    • Karnataka
      • Bangalore、Karnataka、印度、560092
        • Life Care Hospital and Research Centre
    • Kerala
      • Kochi、Kerala、印度、682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Madhya Pradesh
      • Indore、Madhya Pradesh、印度、452010
        • TOTALL Diabetes Hormone Institute
    • Maharashtra
      • Mumbai、Maharashtra、印度、400012
        • Seth GS Medical College & KEM Hospital
      • Pune、Maharashtra、印度、411021
        • Chellaram Diabetes Institute
    • Rajasthan
      • Jaipur、Rajasthan、印度、302006
        • Diabetes, Thyroid and Endocrine Centre
    • Tamil Nadu
      • Vellore、Tamil Nadu、印度、632004
        • Christian Medical College Hospital, Vellore
    • Telangana
      • Hyderabad、Telangana、印度、500082
        • Diabetes Research Center, Hyderabad
      • Chiba、日本、261-0004
        • Tokuyama clinic_Diabetic internal medicine
      • Soka-shi, Saitama、日本、340-0015
        • Soka Sugiura Internal Medicine Clinic
      • Tokyo、日本、104-0031
        • Fukuwa Clinic
      • Tokyo、日本、103-0027
        • Tokyo-Eki Center-building Clinic_Internal Medicine
      • Tokyo、日本、104-0031
        • Fukuwa Clinic_Internal Medicine
    • New South Wales
      • Campbelltown、New South Wales、澳大利亚、2560
        • Campbelltown Hospital
      • Macquarie Park、New South Wales、澳大利亚、2109
        • Macquarie University - Clinical Trials Unit
      • St Leonards、New South Wales、澳大利亚、2065
        • Royal North Shore Hospital
      • Sydney、New South Wales、澳大利亚、2148
        • Western Endocrine Blacktown
      • Sydney、New South Wales、澳大利亚、2148
        • Roger Chih Yu Chen
      • Wollongong、New South Wales、澳大利亚、2500
        • Illawarra Diabetes Service Clinical Trials & Research Unit
    • Queensland
      • Birtinya、Queensland、澳大利亚、4575
        • University of Sunshine Coast - Vitality Village
      • Meadowbrook、Queensland、澳大利亚、4131
        • Logan Hospital
    • South Australia
      • Oaklands Park、South Australia、澳大利亚、5046
        • Southern Adelaide Diabetes & Endocrine Services
    • Victoria
      • Box Hill、Victoria、澳大利亚、3128
        • Eastern Clinical Research Unit Box Hill
      • Camberwell、Victoria、澳大利亚、3124
        • Emeritus Research Melbourne
      • Heidelberg Heights、Victoria、澳大利亚、3081
        • Austin Health, Metabolic Disorders Centre
      • Parkville、Victoria、澳大利亚、3050
        • The Royal Melbourne Hospital
      • Parkville、Victoria、澳大利亚、3050
        • The Royal Melbourne Hospital - Diabetes & Endocrinology Department
    • Western Australia
      • Fremantle、Western Australia、澳大利亚、6160
        • Fremantle Hospital
    • California
      • Chula Vista、California、美国、91911
        • Velocity Clin Res-Chula Vista
      • Fresno、California、美国、93720
        • Valley Research
      • Inglewood、California、美国、90301
        • 310 Clinical Research
      • La Mesa、California、美国、91942
        • Velocity Clin Res San Diego
      • Lancaster、California、美国、93534
        • First Valley Med Grp Lancaster
      • Lomita、California、美国、90717
        • Torrance Clin Res Inst, Inc.
      • Los Alamitos、California、美国、90720
        • Pacific Clinical Studies
      • Los Angeles、California、美国、90057
        • Velocity Clinical Research Westlake
      • Montclair、California、美国、91763
        • Catalina Research Institute, LLC
      • San Diego、California、美国、92123
        • Artemis Insitute for Clin Res
      • Toluca Lake、California、美国、91602
        • Med Partners, Inc.
      • Torrance、California、美国、90505
        • UCLA Health Southbay Endocrine
      • Tustin、California、美国、92780
        • University Clin Investigators
      • Walnut Creek、California、美国、94598
        • Diablo Clinical Research, Inc.
    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Hospital
    • Florida
      • Clearwater、Florida、美国、33756
        • Innovative Research of W Florida Inc.
      • Clearwater、Florida、美国、33756
        • Innovative Research of W FL
      • Miami、Florida、美国、33183
        • International Research Associates, LLC_Miami
    • Georgia
      • Columbus、Georgia、美国、31904
        • Centricity Research
    • Idaho
      • Blackfoot、Idaho、美国、83221
        • Elite Clinical Trials
    • Illinois
      • Peoria、Illinois、美国、61603
        • Methodist Medical Center of Illinois
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa
    • Maryland
      • Columbia、Maryland、美国、21045
        • Centennial Medical Group
      • Oxon Hill、Maryland、美国、20745
        • MD Medical Research
      • Rockville、Maryland、美国、20852
        • Endo And Metab Cons
    • Missouri
      • Springfield、Missouri、美国、65807
        • Clinvest Research
    • Montana
      • Butte、Montana、美国、59701
        • Mercury Str Med Grp, PLLC
    • Nebraska
      • Lincoln、Nebraska、美国、68510
        • Velocity Clinical Research Lincoln
    • Nevada
      • Las Vegas、Nevada、美国、89148
        • Palm Research Center Inc-Vegas
      • Las Vegas、Nevada、美国、89109
        • Excel Clinical Network
    • New York
      • Binghamton、New York、美国、13905
        • Velocity Clinical Research Binghamton
    • North Carolina
      • Greensboro、North Carolina、美国、27408
        • PharmQuest Life Sciences LLC
      • Wilmington、North Carolina、美国、28401
        • Accellacare Wilmington
    • Ohio
      • Canton、Ohio、美国、44718
        • Diab & Endo Assoc of Stark Co
      • Cincinnati、Ohio、美国、45242
        • Velocity Clin Res_Cincinnati
      • Cincinnati、Ohio、美国、45246
        • Velocity Clinical Research Springdale
      • Dayton、Ohio、美国、45439
        • Providence Health Partners Ctr
      • Maumee、Ohio、美国、43537
        • Advanced Med Res Maumee
    • Oregon
      • Grants Pass、Oregon、美国、97527
        • Velocity Clin Res Grants Pass
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19114
        • Tristar Clin Investigations, PC
      • Pittsburgh、Pennsylvania、美国、15243
        • Preferred Primary Care Physicians Inc.
      • Uniontown、Pennsylvania、美国、15401
        • Preferred Primary Care Physicians, Inc.
    • Texas
      • Abilene、Texas、美国、79606
        • Velocity Clinical Research Abilene
      • Austin、Texas、美国、78759
        • Velocity Clin Res Austin
      • Dallas、Texas、美国、75390
        • UT Southwestern Med Center
      • Dallas、Texas、美国、75230
        • Velocity Clinical Res-Dallas
      • Dallas、Texas、美国、75230
        • Zenos Clinical research
      • Forney、Texas、美国、75126
        • Care United Research, LLC
      • Houston、Texas、美国、77004
        • Endocrine Associates Houston
      • Houston、Texas、美国、77043
        • Biopharma Informatic_Houston
      • Irving、Texas、美国、75039
        • Tekton Research
      • Lewisville、Texas、美国、75057
        • Epic Clinical Research
      • Shavano Park、Texas、美国、78231
        • Consano Clinical Research, LLC
    • Virginia
      • Burke、Virginia、美国、22015
        • Burke Internal Medicine & Research
      • Newport News、Virginia、美国、23606
        • TPMG Clinical Research
      • Seoul、韩国、05505
        • Asan Medical Center
      • Seoul、韩国、01830
        • Nowon Eulji Medical Center, Eulji University
      • Seoul、韩国、03181
        • Kangbuk Samsung Hospital
      • Seoul、韩国、02841
        • Korea University Anam Hospital
    • Gyeonggi-do
      • Seongnam-si、Gyeonggi-do、韩国、13620
        • Seoul National University Bundang Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Female of non-childbearing potential, or male.
  • For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
  • Age 18-75 years (both inclusive) at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
  • Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
  • Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
  • Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Dosing scheme A (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

安慰剂比较:Dosing scheme A (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

实验性的:Dosing scheme B (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

安慰剂比较:Dosing scheme B (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

实验性的:Dosing scheme C (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

安慰剂比较:Dosing scheme C (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

实验性的:Dosing scheme D (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

安慰剂比较:Dosing scheme D (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

实验性的:Dosing scheme E (NNC0519-0130)

Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

安慰剂比较:Dosing scheme E (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

有源比较器:Dosing scheme F (tirzepatide)

Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.

Trizepatide will be administered subcutaneously.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Glycated haemoglobin (HbA1c)
大体时间:From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as percentage point (%-point)

From baseline (week 0) to 12 weeks on a given maintenance dose

次要结果测量

结果测量
措施说明
大体时间
Change in Glycated haemoglobin (HbA1c)
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as percentage point (%-point)

From baseline (week 0) to end of treatment (week 36)
Relative change in body weight
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as percentage (%)

From baseline (week 0) to end of treatment (week 36)
Change in body weight
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as kilograms (kg)

From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
大体时间:From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as millimoles per liter (mmol/L)

From baseline (week 0) to 12 weeks on a given maintenance dose
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
大体时间:From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively

Measured as percentage point (%-point)

From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
Change in waist circumference
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as centimeter (cm)

From baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as millimeters of mercury (mmHg)

From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive Protein (hsCRP)
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in total cholesterol
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in triglycerides
大体时间:From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Number of adverse events
大体时间:From baseline (week 0) to end of study (week 40)

Measured as number of events

From baseline (week 0) to end of study (week 40)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Transparency (dept. 2834)、Novo Nordisk A/S

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年3月18日

初级完成 (实际的)

2025年9月19日

研究完成 (实际的)

2025年10月13日

研究注册日期

首次提交

2024年3月16日

首先提交符合 QC 标准的

2024年3月16日

首次发布 (实际的)

2024年3月22日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NN9541-4945
  • U1111-1291-9196 (其他标识符:World Health Organization (WHO))
  • jRCT2031230704 (注册表标识符:JRCT)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅